Business Wire

CA-ALTIUM

25.5.2023 22:17:30 CEST | Business Wire | Press release

Share
Altium Achieves SOC 2 Type 2, Reinforcing Commitment to Data Security and Compliance

Altium, LLC (ASX: ALU), the global leader in PCB design software, announces the successful completion of the Service Organization Control (SOC) 2 Type 2 certification. This significant milestone highlights Altium's dedication to maintaining the highest data security and integrity standards within its cloud-based Altium 365 platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005790/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SOC 2 Type 2 certification underscores Altium's commitment to ensuring data availability, security, and privacy on the Altium 365 collaborative platform for electronics design. (Graphic: Altium LLC)

Completing the examination and the subsequent report receipt verifies that Altium meets or exceeds the rigorous security measures and industry standards outlined by the American Institute of Certified Public Accountants (AICPA) regarding security, availability, and confidentiality.

The Altium 365 Cloud Security team, under the leadership of Volodymyr Volotko, Director of Cloud Solutions, possesses a wealth of expertise in creating secure and compliant environments for Altium 365 customers.

"By successfully completing the SOC 2 Type 2 examination, we demonstrate our commitment to upholding the highest security standards," said Greg Bellasis, Director of Cybersecurity. "Through implementing effective controls, we can confidently assure our customers that their trust in Altium is well-placed."

Following the completion of the SOC 2 Type 1 audit in March 2022, Altium voluntarily pursued the next level of examination, the SOC 2 Type 2. It's important to note that SOC 2 Type 1 assesses the design of security processes at a specific point in time. In contrast, a Type 2 report evaluates the effectiveness of those controls over a specified period of time. The Type 1 examination establishes the foundation of well-designed controls, while the Type 2 examination provides evidence of the controls' effectiveness and ability to operate consistently over time.

Altium plans to participate in annual assessments to maintain active SOC 2 Type 2 reports, further reinforcing its ongoing data security and compliance commitment.

"Altium's achievement of SOC 2 Type 2, our recent AWS GovCloud offering, and continued progress reaffirm our commitment to delivering the highest levels of security, privacy, and continuity to our clients," stated Nikolay Ponomarenko, Head of Altium 365 Cloud Platform. "We consistently enhance our data management practices, fostering transparency, open communication, and accountability between our customers and ourselves, continuing to invest towards security."

Altium provides a comprehensive Trust Center equipped with a knowledge base to assist users in comprehending the security and compliance features of Altium 365. Further information about SOC 2 and other compliance-related topics can be found by visiting the Altium 365 Trust Center at altium.com/trust.

About Altium:

Altium, LLC (ASX: ALU) is a global software company headquartered in San Diego, California, who are accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005790/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye